data + articles · 3 listed
newest 2011spec sheet11 rows
Adipotide, also known as prohibitin-targeting peptide-1, is an experimental peptide designed to cause weight loss by destroying the blood supply of white fat. It works by homing to the vasculature that feeds fat tissue and triggering the death of those blood vessels, which starves the surrounding fat cells. Developed in academic cancer-research laboratories, it produced rapid weight loss in obese mice and monkeys but remains investigational and has not been approved for human use.
- Novel fat-targeting mechanism
- Produced fat loss in primate studies
- Research interest for obesity
- Reversible changes in kidney function were seen in animal studies, marking the kidney as a concern
Overview
Adipotide is a synthetic peptidomimetic, a short engineered peptide-like molecule, sometimes written as prohibitin-targeting peptide-1 [2]. Its design joins two functional parts: a homing sequence that recognizes the blood vessels supplying white fat and a second segment that induces programmed cell death once the molecule reaches its target [1][2]. It emerged from work at the University of Texas MD Anderson Cancer Center, where researchers used a technique called in vivo phage display to isolate a peptide that specifically binds the vasculature of fat tissue [1].
The homing portion of adipotide latches onto prohibitin, a membrane protein that the developers established as a marker of the blood vessels feeding white adipose tissue [1][3]. By delivering a pro-apoptotic cargo to these vessels, the peptide causes them to regress, cutting off the fat's blood supply so that the fat itself is resorbed [1]. Later mapping studies in patients confirmed that the prohibitin partner it exploits is indeed concentrated in the vasculature of white fat, supporting the targeting concept [3].
In animal experiments the approach produced marked results: obese mice lost weight and normalized their metabolism, and in a study of obese rhesus monkeys the peptide caused rapid weight loss and improved insulin resistance, with reductions in white fat confirmed by imaging [1][2]. The same primate work, however, documented dose-related and reversible changes in kidney function, flagging the kidney as a site of concern [2]. Adipotide has been described as the prototype of a new class of candidate obesity drugs, but it remains experimental; it has not been approved for human use, and its development did not advance into routine clinical practice [2].
Mechanism
Adipotide is built from two joined elements that give it a targeted, self-contained mechanism. The first is a short homing motif with the sequence CKGGRAKDC, identified by screening libraries in living animals, which selectively recognizes the blood vessels that supply white adipose tissue [1]. The second is a pro-apoptotic that disrupts membranes and triggers programmed cell death once it becomes concentrated inside the target cells [2].
The homing sequence binds prohibitin, a multifunctional membrane protein that the developers identified as a distinctive marker of the endothelial cells lining white fat vasculature [1][3]. By anchoring to prohibitin and delivering its death-inducing segment, adipotide drives the targeted blood vessels to undergo apoptosis and regress. Deprived of their blood supply, the fat cells that depended on those vessels are resorbed, producing loss of white adipose tissue and, in animal models, reversal of obesity along with improved handling of [1][2]. Because the prohibitin target is also present in the fat vasculature of primates, the effect carried over from rodents to monkeys, though the kidney proved sensitive to the , showing reversible changes in proximal tubule function at higher exposures [2][3].
receptor fingerprint
Prohibitin on fat vasculaturebinds
Adipose vascular endotheliuminduces apoptosis
White adipose tissuereduces
Kidney tissuetoxic effect
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
This is a highly experimental peptide with documented dose-dependent kidney toxicity in animal studies and no established human safety data. It is not an approved therapy. Given the serious organ-toxicity signal, self-experimentation carries substantial risk, and I strongly advise against it.
Subjective profileweighing the evidence above
Hard pass. The mechanism is clever but it showed kidney toxicity in animals and has no established human safety. Not worth it.
Resources
This entry is here for reference.
Research
- 2004first citedReversal of obesity by targeted ablation of adipose tissue
- 2011most recentA peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obes…
- 1.Reversal of obesity by targeted ablation of adipose tissue
- 2.A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
- 3.Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients
3 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Does adipotide really melt fat?
In animals it caused fat loss by destroying the blood supply to fat tissue, but that same mechanism carries serious risks.
Is it safe for humans?
No, it showed kidney toxicity in primates and has no established human safety data.
Is it approved anywhere?
No, it remains an experimental research peptide.
How is it different from GLP-1 drugs?
Completely different; GLP-1 drugs work on appetite and metabolism, while adipotide physically kills fat vasculature.
Should I try it?
Strongly inadvisable given the toxicity signal and lack of human data.
Adverse effects
- Reversible changes in kidney function were seen in animal studies, marking the kidney as a concern
Notes and cautions
- As an experimental agent, its full human safety profile is not established
- Its action on fat is broad rather than limited to one area
- It has not been approved or tested in large human trials
- Long-term consequences of ablating fat vasculature remain unknown